RecruitingPhase 2NCT06359847

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy

Sponsor

Beijing Scitech-Mq Pharmaceuticals Limited

Enrollment

60 participants

Start Date

Nov 15, 2023

Study Type

INTERVENTIONAL

Conditions

Differentiated Thyroid Carcinoma

Summary

ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing an experimental drug called ST-1898 in people with thyroid cancer that has spread or cannot be removed by surgery, and that no longer responds to radioiodine treatment (the standard thyroid cancer therapy that uses radioactive iodine to destroy cancer cells). **You may be eligible if...** - You are 18 or older - You have locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hurthle cell, or poorly differentiated) that cannot be surgically removed - Your cancer has stopped responding to radioiodine therapy (it is RAI-refractory) - You have at least one measurable lesion - Your life expectancy is at least 12 weeks - Your organ function (liver, kidneys, blood counts) is adequate **You may NOT be eligible if...** - Your cancer is anaplastic (undifferentiated) thyroid cancer or medullary thyroid cancer - You have another active cancer - You have significant heart problems or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGST-1898 tablets

Tablets: 5 mg and 40 mg

Locations(1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06359847